Cargando…

Treatment of metastatic prostate cancer after STAMPEDE

Detalles Bibliográficos
Autor principal:	Wolf, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422685/ https://www.ncbi.nlm.nih.gov/pubmed/28540244 http://dx.doi.org/10.21037/tau.2017.02.01

Ejemplares similares

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
por: Sharma, Aditya Prakash, et al.
Publicado: (2018)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials
por: van Soest, Robert J., et al.
Publicado: (2015)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
por: Parker, Chris C., et al.
Publicado: (2022)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
por: Parker, Christopher C, et al.
Publicado: (2018)

Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems
por: Greasley, Rosa U., et al.
Publicado: (2018)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Hajj Stampede in Mina, 2015: Need for Intervention
por: Salamati, Payman, et al.
Publicado: (2016)

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
por: Parker, Chris
Publicado: (2018)

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
por: Clarke, N W, et al.
Publicado: (2019)

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

Psychiatric morbidity in school children who suffered a stampede
por: Bhatia, Manjeet S., et al.
Publicado: (2012)

Public Health Lesson from Shanghai New Year’s Eve Stampede
por: Huang, Yuee, et al.
Publicado: (2015)

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
por: Parry, Marina A., et al.
Publicado: (2023)

Emergency preparedness for mass gatherings: Lessons of “12.31” stampede in Shanghai Bund
por: Dong, Yong-He, et al.
Publicado: (2017)

Comparing Two Epidemiologic Surveillance Methods to Assess Underestimation of Human Stampedes in India
por: Ngai, Ka Ming, et al.
Publicado: (2013)

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
por: Gilson, C., et al.
Publicado: (2017)

Should Early Use of Chemotherapy Be Avoided in the Treatment of Metastatic Prostate Cancer?
por: Kimura, Takahiro
Publicado: (2021)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
por: Attard, Gerhardt, et al.
Publicado: (2022)

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003
por: Clarke, N.W., et al.
Publicado: (2020)

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
por: Sydes, M R, et al.
Publicado: (2018)

Stampede Prevention Design of Primary School Buildings in China: A Sustainable Built Environment Perspective
por: Xie, Kefan, et al.
Publicado: (2018)

Recent Scientific Developments in Metastatic Prostate Cancer
por: Heidegger, Isabel
Publicado: (2020)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2012)

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
por: Woods, Beth S., et al.
Publicado: (2018)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
por: James, Nicholas D., et al.
Publicado: (2022)

Non-invasive actionable biomarkers for metastatic prostate cancer
por: Luo, Jun
Publicado: (2016)

Fly Stampede 2.0: A Next Generation Optomotor Assay for Walking Behavior in Drosophila Melanogaster
por: Kim, Soomin, et al.
Publicado: (2016)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2016)

Rapid bench to bed in management of metastatic prostate cancer
por: Balaji, K. C.
Publicado: (2016)

How to deal with steroids use in the management of metastatic prostate cancer during pandemic
por: Baboudjian, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9948hfttjcgtjcfj1v0cv0kliu